Yazar "Ocal, Ramazan" için listeleme
-
Effectiveness of Bendamustine in Relapse or Refractory Lymphoma Cases: A Report From Turkey-The Turkish Oncology Group (TOG) Study.
Karadurmus, Nuri; Paydas, Semra; Ocal, Ramazan; Yildiz, Birol; Nayir, Erdinc; Dogan, Mutlu; Sumbul, Ahmet Taner; Surmeli, Zeki; Barista, Ibrahim; Ferhanoglu, Burhan; Ozgur, Gokhan; Erturk, Ismail; Ozaydin, Sukru; Petekkaya, Halil Ibrahim; Uskent, Necdet (2017) -
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study
Karadurmus, Nuri; Paydas, Semra; Esin, Ece; Surmeli, Zeki Gokhan; Yildiz, Birol; Erturk, Ismail; Nayir, Erdinc; Dogan, Mutlu; Sumbul, Ahmet Taner; Barista, Ibrahim; Gurkan, Emel; Ocal, Ramazan; Ferhanoglu, Burhan; Ozgur, Gokhan; Karakas, Yusuf; Lacin, Sahin; Ozaydin, Sukru; Petekkaya, Halil İbrahim; Uskent, Necdet (2021)Introduction: We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey. Material and methods: In this retrospective study, we included relapsed/refractory ... -
Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
Savas, Emine Merve; Yilmaz, Seda; Dikyar, Ayse Asena Baser; Ozkurt, Zubeyde Nur; Ocal, Ramazan; Can, Ferda; Pepeler, Sezgin; Kaynar, Lale Aydin; Gokcen, Sanem; Yildiz, Abdulkerim; Albayrak, Murat; Karakus, Sema; Ceneli, Ozcan; Yagci, Munci (2023)Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality ...